F33 F31
Conditions
Interventions
Group 1: Patients receive at baseline (directly after inclusion into the study) and after five weeks of treatment (W5) an assessment of the severity of the depressive episode by means of the Hamilton-
Sponsors
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: patients aged between 18 and 60 who are able to give consent inpatient treatment due to a depressive episode (ICD-10 F31, F32, F33; HAMD-21: 18-30) after written informed consent
Exclusion criteria
Exclusion criteria: • pregnant or brest-feeding women • drug or alcohol dependence • dementia • depressive episode secondary of a somatic/neurological illness or substance abuse • severe somatic or neurological illness which can impair results (e.g. Morbus Cushing, rheumathoid illness) • other psychiatric comorbidities • The patient cannot understand the scope of the study and is not capable of giving consent. • admission to hospital not voluntary • regular intake of steroids or non-steroidal antiphlogistics (NSAID)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CCR5 level: baseline and after 5 weeks (W5) CANTAB scores: baseline and after 5 weeks (W5) HAMD-21 sum scores: baseline and after 5 weeks (W5) We want to assess if their is a clinical improvement after 5 weeks of treatment (HAMD-21) and if this is in relation to an improvement of depression-associated cognitive dysfunction (CANTAB) and if there is a correlation with CCR5 levels, which has already been shown to influence learning and memory in animal models. | — |
Secondary
| Measure | Time frame |
|---|---|
| CCL5 levels IL-1 beta levels TNF-alpha levels IL-6 levels BDI scores | — |
Countries
Germany
Contacts
Public ContactCaroline Nothdurfter
Klinik für Psychiatrie und Psychotherapie der Universität Regensburg
Outcome results
None listed